Cargando…

Author Correction: Accelerated single cell seeding in relapsed multiple myeloma

Detalles Bibliográficos
Autores principales:	Landau, Heather J., Yellapantula, Venkata, Diamond, Benjamin T., Rustad, Even H., Maclachlan, Kylee H., Gundem, Gunes, Medina-Martinez, Juan, Ossa, Juan Arango, Levine, Max F., Zhou, Yangyu, Kappagantula, Rajya, Baez, Priscilla, Attiyeh, Marc, Makohon-Moore, Alvin, Zhang, Lance, Boyle, Eileen M., Ashby, Cody, Blaney, Patrick, Patel, Minal, Zhang, Yanming, Dogan, Ahmet, Chung, David J., Giralt, Sergio, Lahoud, Oscar B., Peled, Jonathan U., Scordo, Michael, Shah, Gunjan, Hassoun, Hani, Korde, Neha S., Lesokhin, Alexander M., Lu, Sydney, Mailankody, Sham, Shah, Urvi, Smith, Eric, Hultcrantz, Malin L., Ulaner, Gary A., van Rhee, Frits, Morgan, Gareth J., Landgren, Ola, Papaemmanuil, Elli, Iacobuzio-Donahue, Christine, Maura, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817844/ https://www.ncbi.nlm.nih.gov/pubmed/33473129 http://dx.doi.org/10.1038/s41467-021-20978-y

Ejemplares similares

Accelerated single cell seeding in relapsed multiple myeloma
por: Landau, Heather J., et al.
Publicado: (2020)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

P962: COMMERCIAL TECLISTAMAB IN ANTI-BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE.
por: Firestone, Ross, et al.
Publicado: (2023)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

P886: AFRICAN AMERICAN PATIENTS WITH SMOLDERING MULTIPLE MYELOMA MAY HAVE A LOWER RISK OF PROGRESSION COMPARED TO WHITE PATIENTS
por: Akhlaghi, T., et al.
Publicado: (2022)

Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients
por: Kazandjian, Dickran, et al.
Publicado: (2019)

Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls
por: Shah, Urvi A., et al.
Publicado: (2021)

Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
por: Maclachlan, Kylee H., et al.
Publicado: (2021)

Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study
por: Korde, Neha, et al.
Publicado: (2023)

Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone
por: Korde, Neha, et al.
Publicado: (2021)

Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment
por: Hultcrantz, Malin, et al.
Publicado: (2020)

Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma
por: Yellapantula, Venkata, et al.
Publicado: (2019)

Correction: Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma
por: Yellapantula, Venkata, et al.
Publicado: (2020)

Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations
por: Maclachlan, Kylee H., et al.
Publicado: (2022)

COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers
por: Hultcrantz, Malin, et al.
Publicado: (2020)

Isabl Platform, a digital biobank for processing multimodal patient data
por: Medina-Martínez, Juan S., et al.
Publicado: (2020)

Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma
por: Rustad, Even H., et al.
Publicado: (2019)

Nutrition perceptions, needs and practices among patients with plasma cell disorders
por: Malik, Maria A., et al.
Publicado: (2022)

Circulating adiponectin levels differ between patients with multiple myeloma and its precursor disease
por: Hofmann, Jonathan N, et al.
Publicado: (2017)

Extreme body mass index and survival in newly diagnosed multiple myeloma patients
por: Shah, Urvi A., et al.
Publicado: (2023)

COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
por: Hultcrantz, Malin, et al.
Publicado: (2020)

Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities
por: Oben, Bénedith, et al.
Publicado: (2021)

An unusual genomic variant of pancreatic ductal adenocarcinoma with an indolent clinical course
por: Kohutek, Zachary A., et al.
Publicado: (2017)

Local recurrences at the anastomotic area are clonally related to the primary tumor in sporadic colorectal carcinoma
por: Vakiani, Efsevia, et al.
Publicado: (2017)

Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10–49 years old: a population-based study from the National Health and Nutrition Examination Survey
por: Landgren, O, et al.
Publicado: (2017)

Pancreatic cancer genomics: insights and opportunities for clinical translation
por: Makohon-Moore, Alvin, et al.
Publicado: (2013)

Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
por: Landgren, Ola, et al.
Publicado: (2016)

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
por: Huang, Phoebe A., et al.
Publicado: (2019)

Pre-Diagnosis Dietary Patterns and Risk of Multiple Myeloma in the NIH-AARP Diet and Health Study
por: Castro, Francesca, et al.
Publicado: (2023)

Neoantigen quality predicts immunoediting in survivors of pancreatic cancer
por: Łuksza, Marta, et al.
Publicado: (2022)

Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms
por: Gao, Qi, et al.
Publicado: (2018)

Subclonal somatic copy number alterations emerge and dominate in recurrent osteosarcoma
por: Kinnaman, Michael D., et al.
Publicado: (2023)

Tumor diversity and evolution revealed through RADseq
por: Perry, Elizabeth B., et al.
Publicado: (2017)

Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma
por: Kinnaman, Michael D., et al.
Publicado: (2023)

Timing the initiation of multiple myeloma
por: Rustad, Even H., et al.
Publicado: (2020)

P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2
por: Leleu, Xavier, et al.
Publicado: (2023)

Dietary intake is associated with risk of multiple myeloma and its precursor disease
por: Thordardottir, Marianna, et al.
Publicado: (2018)

Kennedy's Disease: A Second Genetically Confirmed Report from India
por: Shah, Rutul, et al.
Publicado: (2021)

Reconstructing metastatic seeding patterns of human cancers
por: Reiter, Johannes G., et al.
Publicado: (2017)

Characterization of genetic subclonal evolution in pancreatic cancer mouse models
por: Niknafs, Noushin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gov06k33h7eajht1h97k5t7oi4